Sign inCreate account

Report workspace tools

NCT04734860WITHDRAWNanonymous

A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

Sponsor

Source record

Sorrento Therapeutics, Inc.

Phase

Source record

Phase 2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

COVID-19

Indication / condition

AI-normalized

Covid19

Intervention

Source record

COVI-AMG, Placebo

Source & freshness

Source record

NCT ID

NCT04734860

Original source

ClinicalTrials.gov

Source last updated

Feb 25, 2022

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04734860

Title

A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

Sponsor

Sorrento Therapeutics, Inc.

Status

WITHDRAWN

Phase

Phase 2

Condition raw

Covid19

Condition normalized

Covid19

Modality raw

Covid19

Modality normalized

monoclonal antibody

Target raw

COVID-19

Target normalized

COVID-19

Interventions

COVI-AMG, Placebo

Public preview

Source record

Sorrento Therapeutics, Inc. initiated a randomized, placebo-controlled trial to evaluate the safety and efficacy of STI-2020 (COVI-AMG™), a neutralizing monoclonal antibody for adults with mild COVID-19 symptoms. The study was designed to assess pharmacokinetics and patient outcomes over a 70-day follow-up period.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04734860

Status

WITHDRAWN

Phase

Phase 2

Sponsor

Sorrento Therapeutics, Inc.

Executive brief

Investment-Ready Snapshot

Sorrento Therapeutics, Inc. initiated a randomized, placebo-controlled trial to evaluate the safety and efficacy of STI-2020 (COVI-AMG™), a neutralizing monoclonal antibody for adults with mild COVID-19 symptoms. The study was designed to assess pharmacokinetics and patient outcomes over a 70-day follow-up period.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 25, 2022
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04734860

Indication

Covid19

Modality

monoclonal antibody

Target

COVID-19

Intervention

COVI-AMG, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.